WASHINGTON, Jan. 21 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration announced the approval of Rhapsido, also known as remibrutinib, marking the successful redemption of a rare pediatric disease priority review voucher. The decision follows a regulatory process designed to encourage the development of treatments for conditions affecting children.

Under section 529 of the Federal Food, Drug, and Cosmetic Act, the agency manages a program that a . . .

Click here for more information about our products